Please assess the completion status of the following clinical trial:

Trial Title: Intestinal Phosphate Transporter Expression in CKD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Upper endoscopy for suspected or known esophageal or gastric pathology~* Upper endoscopy for screening purposes~* Written consent to take part in the study~Exclusion Criteria:~* Food intake within 8 hours prior to the endoscopy~* Major duodenal pathology, in particular duodenitis or duodenal ulcers or tumor~* Contraindication to duodenal biopsy such as bleeding disorder~* Treatment with medication known to regulate the expression or activity of intestinal phosphate transporters (e.g. nicotinamide)~* Kidney transplant patients~* Alcohol or drug abuse~* Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study~* Participation in a parallel clinical trial~* Subjects who are in any state of dependency to the sponsor or the investigators~* Employees of the sponsor or the investigators~* Subjects who have been committed to an institution by legal or regulatory order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- normal renal function (Type: EXPERIMENTAL): Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
- CKD stage 3-5 (not on dialysis) (Type: EXPERIMENTAL): Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
- on dialysis (Type: EXPERIMENTAL): Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.

Based on this trial design, predict the completion outcome and termination type (if applicable).